Company: HURA
Filing Date: 2025-06-06
Form Type: 425
Source: 0001193125-25-137145
Chunk: 35

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 425
Chunk 35
---
 (a) it is an investment company registered under the Investment Company Act of 1940, as amended, (b) that it is advised by an investment
adviser subject to regulation under the Investment Advisers Act of 1940, as amended, or (c) that its internal compliance policies and procedures so require it, then (1) prior to the delivery by such Investor on the Applicable Closing Date
of the purchase price for the Shares such Investor is purchasing pursuant to this Agreement, the Company shall deliver to the Investor evidence of the issuance of such Investor’s Shares from the Transfer Agent in form and substance reasonably
acceptable to the Investor, and electronic copies of the executed Warrants, and (2) following receipt of such evidence, such Investor shall deliver on the Applicable Closing Date its purchase price for such Securities. For avoidance of doubt,
the Second, Third and Fourth Closings may occur in any chronological order and are not conditioned on any other closings.

First Closing. The initial closing of the purchase and sale of 25% of subscription amount set forth on each Investor’s signature page (the “First Closing”) shall be on the date that is one Business Day
following the date of this Agreement (the “First Closing Date”).

Second Closing. The closing
of the purchase and sale of 25% of the subscription amount set forth on each Investor’s signature page (the “Second Closing”) shall be the date that is three Business Days following the date on which the Company notifies the
Investors in writing that the FDA has notified the Company in writing or by email that the Company is no longer subject to the partial clinical hold set forth in the FDA’s Partial Clinical Hold letter to the Company dated January 24, 2024
(the “Second Closing Date”).

Third Closing. The closing of the purchase and sale of 25% of the
subscription amount set forth on each Investor’s signature page (the “Third Closing”) shall be the date that is three Business Days following the date on which the Company notifies the Investors that the Phase 3 trial for IFx-Hu2.0 (the “Phase 3 Trial”) has been initiated (the “Third Closing Date”).

5

Fourth Closing. The closing of the purchase and sale of 25% of the
subscription amount set forth on each Investor’s signature page (the “Fourth Closing”) shall be the date that is three Business Days following the date on which the Company notifies the Investors that all material conditions
for the closing